📇 Rhumatologue · BOURGES CEDEX · (18) · Salarié

MME FABIENNE REBILLOUT

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
25 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
73 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 BOURGES CEDEX (18)SalariéRPPS 10002094877

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(2)

CH GEORGE SAND BOURGES
77 R LOUIS MALLET BP 6050, 18024 BOURGES CEDEX
☎ 0248672000Activité de soin et de pharmacie🏥 Centre CH ↗
DOCTEUR REBILLOUT FABIENNE
HOPITAL PRIVE GUILLAUME DE VARYE 210 ROUTE DE VOUZERON, 18230 ST DOULCHARD

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial

European journal of cancer (Oxford, England : 1990) · 2020

📚 88 citations🎯 RCR 3.93Top 11% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Does freezing in Parkinson's disease change limb coordination? A kinematic analysis

Journal of neurology · 2007

📚 57 citations🎯 RCR 2.10🔓 Open Access

A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis

Lupus · 2008

📚 37 citations🎯 RCR 1.46🩺 Clinique

Lire l'abstract Crossref ↓

Mycophenolate mofetil (MMF) with prednisolone has been associated with high remission rates when used as induction treatment for lupus nephritis. This prospective, multicentre, cohort study investigates the efficacy and safety of this regimen over 24 weeks in 213 Chinese patients with active lupus nephritis (Classes III, IV, V or combination). Baseline activity index (AI) was 6.91 ± 3.33 and chronicity index (CI) was 1.9 ± 1.2. The remission rate was 82.6% at 24 weeks (complete remission, 34.3%; partial remission, 48.4%). There were significant ( P < 0.01) improvements in kidney function shown by reductions in proteinuria, serum albumin, serum creatinine and creatinine clearance, as well as in systemic lupus erythematosus disease activity index (SLEDAI) scores. Independent risk factors influencing remission were pathological classification (including Class V and III or Class V and IV nephritis) and elevated serum creatinine at baseline (OR 2.967, 95% CI: 1.479–6.332, P = 0.001 and OR 1.007, 95% CI: 1.002–1.011, P = 0.001, respectively). Patients with concomitant membranous features on biopsy had a lower remission rate than those with Class III and IV nephritis (66.7% vs 87.3%, P = 0.002). Renal biopsy was repeated in 25 patients following treatment. There was a transition to less severe pathological morphologies in majority of subjects. Infections were monitored throughout treatment: eight patients (3.8%) experienced bacterial infections, whereas herpes zoster occurred in seven patients. Nine patients (4.2%) suffered from gastrointestinal upset, which resolved without discontinuation of MMF. One patient became leucopenic, whereas another died from active disease unrelated to kidney symptoms. MMF combined with prednisolone is an effective and well-tolerated induction treatment for patients with active lupus nephritis and for controlling SLE systemic activity.

Cookies & analyse de trafic

MME FABIENNE REBILLOUT

Pourquoi vous devez consulter ce praticien

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (25) — classées par pathologie

Transversal16

Corticothérapie2

Qualité de vie / PROMs2

Épidémiologie & registres1

Essai clinique1

Lupus1

Revue générale1

Vraie vie / RWE1

Partager cette fiche